Trial Archive

Some of the trials we have been proud to support with our Spinnaker Platform. All these studies are now closed and results have been published. Enjoy the read!

CAMERA

A multi-centre randomised controlled trial to determine if 7 days of intravenous β-lactam in combination with standard therapy will lead to better complication-free survival 90-days after randomisation, compared to standard therapy alone in patients with MRSA blood stream infection.

HEAT

A phase 2b randomised controlled trial investigating the safety and efficacy of intravenous paracetamol versus placebo (5% dextrose) in the treatment of fever in critically ill patients with known or suspected infection.

ICU-ROX

A multi-centre, randomised, single blinded clinical trial comparing standard vs. conservative oxygen therapy in mechanically ventilated adults in the Intensive Care Unit.

REACTOR

A multi-centre, phase II, randomised, open label, clinical trial comparing combined prophylactic intravenous paracetamol and early targeted physical cooling for fever with standard temperature management in mechanically ventilated adults without acute brain pathologies who are expected to be ventilated beyond the day after randomisation.

TARGET

A 4,000 patient, multi-centre, double-blinded, randomised, controlled, parallel-group, phase III clinical trial to determine if augmentation of calorie delivery using energy dense enteral nutrition in mechanically ventilated patients improves 90 day survival when compared to routine care.

TARGET Protein Feasibility Study

The TARGET Protein Feasibility Study is a 120 patient, multi-centre, double-blinded, randomised, controlled, parallel-group, feasibility clinical trial.
The primary aim of the study is to determine if separation of mean daily protein delivery can be achieved using a higher protein enteral nutrition (EN) when compared to routine care EN, in mechanically ventilated patients.

TASI

The TASI Study will tested the potential overall benefit of the TightRope versus syndesmotic screw fixation for ankle injuries.

Novel START

A 52- week, open label, parallel group, multi-centre, phase III, randomised controlled trial to compare the efficacy and safety of three asthma treatment regimens. Recruitment in New Zealand, Australia, Italy and the United Kingdom.

PRACTICAL

A 52- week, open label, parallel group, multi-centre, phase III, randomised controlled trial to compare the efficacy and safety of two asthma treatment regimens. Recruitment in New Zealand only.

SPLIT

A novel, multi-centred cluster randomised double cross over feasibility trial
investigating the effect of using 0.9% saline or Plasma Lyte® 148 as fluid therapy in intensive care patients on the risk of developing acute kidney injury.

Supp PN

A stratified, prospective, multi-centre, unblinded, randomised, parallel-group phase II study to determine whether a supplemental parenteral nutrition strategy will reliably and safely increase energy intake when compared to usual care.

Our platform has been used in over 300 hospitals across the globe.

To find out more about any of these projects –
just get in touch